These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
760 related articles for article (PubMed ID: 20443786)
21. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434 [TBL] [Abstract][Full Text] [Related]
22. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215 [TBL] [Abstract][Full Text] [Related]
23. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Zhou B; Yang DQ; Xie F Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105 [TBL] [Abstract][Full Text] [Related]
24. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606 [TBL] [Abstract][Full Text] [Related]
25. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452 [TBL] [Abstract][Full Text] [Related]
27. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741 [TBL] [Abstract][Full Text] [Related]
28. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status. Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583 [TBL] [Abstract][Full Text] [Related]
29. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Piper GL; Patel NA; Patel JA; Malay MB; Julian TB Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054 [TBL] [Abstract][Full Text] [Related]
31. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812 [TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518 [TBL] [Abstract][Full Text] [Related]
33. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830 [TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy]. Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Tan QX; Qin QH; Yang WP; Mo QG; Wei CY Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769 [TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. Iwata H Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250 [TBL] [Abstract][Full Text] [Related]
37. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. von Minckwitz G; Untch M; Nüesch E; Loibl S; Kaufmann M; Kümmel S; Fasching PA; Eiermann W; Blohmer JU; Costa SD; Mehta K; Hilfrich J; Jackisch C; Gerber B; du Bois A; Huober J; Hanusch C; Konecny G; Fett W; Stickeler E; Harbeck N; Müller V; Jüni P Breast Cancer Res Treat; 2011 Jan; 125(1):145-56. PubMed ID: 21042932 [TBL] [Abstract][Full Text] [Related]
38. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721 [TBL] [Abstract][Full Text] [Related]
39. Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation. Wilkinson JB; Reid RE; Shaitelman SF; Chen PY; Mitchell CK; Wallace MF; Marvin KS; Grills IS; Margolis JM; Vicini FA Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e159-64. PubMed ID: 21345613 [TBL] [Abstract][Full Text] [Related]
40. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]